Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 13/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932413 | 0.93 | PDE10A (0.41) | SMOTP53ALDH1A1 | |
| SCHEMBL9932464 | 0.89 | AURKA (0.41) | SMOTP53RXFP1AURKAAURKB | |
| SCHEMBL9931786 | 0.89 | CKS1B (0.50) | SMOAURKAAURKBCKS1BSKP1 | |
| SCHEMBL9932557 | 0.87 | SMO (0.43) | SMO | |
| SCHEMBL9968369 | 0.86 | SMO (0.44) | SMO | |
| SCHEMBL9932788 | 0.85 | SMO (0.48) | SMO | |
| SCHEMBL9932685 | 0.83 | SMO (0.54) | SMO | |
| SCHEMBL9932796 | 0.83 | SMO (0.47) | SMOFAAHEPHX2 | |
| SCHEMBL9932181 | 0.82 | SMO (0.47) | SMO | |
| SCHEMBL9931559 | 0.82 | SMO (0.47) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885TP53 323/4885RXFP1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.